Browse studies

Find your next paid study

21 recruiting studies matching your filters

Phase I Study of Adoptive Immunotherapy of Refractory Viral Infection With ex Vivo Expanded Rapidly Generated Virus Specific T (R-MVST) Cells

The primary objective is to determine the safety and feasibility of administering R-MVST cells to patients with refractory viral reactivation and/or symptomati…

Epstein-Barr Virus InfectionsCytomegalovirus InfectionsAdenovirus+1 more

Estimated

~$10 – $6,250

Columbia UniversityNCT05183490

Cytomegalovirus (CMV) Transmission and Immune Tracking (TransmIT) Study: An Observational Study to Evaluate CMV Transmission and Immune Correlates of Viral Shedding Among Young Children in Early Education and Care Settings

The goal of STAGE I of the CMV TransmIT Study is to determine the prevalence of CMV shedding in children up to and including 36 months of age in large group ch…

Cytomegalovirus Infections

Estimated

~$10 – $750

University of Massachusetts, WorcesterNCT06522880

Phase 2

Haplo-identical Viral-Specific T-cells for Treatment of Cytomegalovirus and Adenovirus Infections After Hematopoietic Cell Transplantation

The investigators want to learn if CMV- and ADV-specific T-cells (cells that fight infections) isolated (selected) from a donor using an automated medical devi…

CytomegalovirusAdenovirus

Estimated

~$10 – $6,250

St. Jude Children's Research HospitalNCT05664126

Phase 2

A Phase IIa, Open-label, Multiple Ascending Dose Confirmation Study of the Safety and Tolerability of Intravenous Administration of Brincidofovir in Subjects With Adenovirus Infection or Cytomegalovirus Infection

The purpose of this study is to determine the safety and tolerability of intravenous (IV) brincidofovir (BCV; SyB V-1901) 0.2 mg/kg, 0.3 mg/kg or 0.4 mg/kg dos…

Adenovirus InfectionsCytomegalovirus Infection

Estimated

~$10 – $8,750

SymBio PharmaceuticalsNCT04706923

Phase 2

A Pilot Study in the Treatment of Refractory Cytomegalovirus (CMV) Infections With Related Donor CMV Specific Cytotoxic T-cells (CTLs) in Children, Adolescents and Young Adult Recipients

CMV cytotoxic T cells (CTLs) manufactured with the Miltenyi CliniMACS Prodigy Cytokine Capture System will be administered in children, adolescents and young a…

Cytomegalovirus InfectionsPrimary Immune Deficiency Disorder

Estimated

~$10 – $6,250

New York Medical CollegeNCT03266640

Phase 1

Antigen Specific Adoptive T Cell Therapy for Opportunistic Cytomegalovirus Infection Occurring After Stem Cell Transplant

The purpose of this study is to determine if a specific type of cell-based immunotherapy, using T-cells from a donor that are specific against cytomegalovirus …

Cytomegalovirus InfectionsHematopoietic Stem Cell TransplantOpportunistic Infections

Estimated

~$10 – $7,500

Mari DallasNCT02982902

Phase 4

Exploratory Use of CMV Immunoglobulin in High Risk (D+R-) Transplant Recipients at the End of Antiviral Prophylaxis to Decrease the Risk of Late CMV Infection

This study is being done to find out if administering CytoGam® after the end of standardly prescribed preventive antiviral treatment can help transplant recipi…

CytomegalovirusOrgan TransplantKidney Transplant; Complications+2 more

Estimated

~$10 – $7,500

Camille N. Kotton, MDNCT06958796

Phase 4

A Pilot Trial of the Tolerability and Clinical Effectiveness of Letermovir When Used for Secondary Prophylaxis to Prevent Recurrent Cytomegalovirus Disease in Solid Organ Transplant Recipients

This is a research study to test the tolerability and clinical effectiveness of the study drug, Letermovir (LET), when used as secondary prophylaxis following …

Cytomegalovirus InfectionsInfection in Solid Organ Transplant RecipientsNeutropenia+1 more

Estimated

~$10 – $6,250

Tufts Medical CenterNCT05626530

Phase 1

Viral Specific T-Lymphocytes by Cytokine Capture System (CCS) to Treat Infection With Adenovirus, Cytomegalovirus or Epstein-Barr Virus After Hematopoietic Cell Transplantation or Solid Organ Transplantation and in Patients With Compromised Immunity

The primary purpose of this phase I/II study is to evaluate whether partially matched, ≥2/6 HLA-matched, viral specific T cells have efficacy against adenoviru…

AdenovirusCytomegalovirus InfectionsEpstein-Barr Virus Infections

Estimated

~$10 – $7,500

Jessie L. AlexanderNCT06909110